Topical Tranexamic Acid in Primary Breast Augmentation Surgery: Short- and Long-term Outcomes.
Journal
Aesthetic surgery journal
ISSN: 1527-330X
Titre abrégé: Aesthet Surg J
Pays: England
ID NLM: 9707469
Informations de publication
Date de publication:
10 Jul 2023
10 Jul 2023
Historique:
received:
08
06
2023
revised:
03
07
2023
accepted:
03
07
2023
medline:
10
7
2023
pubmed:
10
7
2023
entrez:
10
7
2023
Statut:
aheadofprint
Résumé
Breast augmentation mammoplasty (BAM) remains to be the most popular cosmetic procedure done worldwide. Bleeding in this procedure increases the chance of capsular contracture. Tranexamic acid (TXA), an anti-fibrinolytic, has been widely used by other surgical specialties to reduce bleeding. We aimed to evaluate the use of TXA in BAM surgery. This is a single-surgeon case series of all patients who underwent primary BAM from March 2017 to March 2018 and received topical TXA spray to the implant pocket prior to implant insertion. Early postoperative complications and long-term outcomes, such as capsular contracture and revision surgery, were recorded and described. Two hundred and eighty-eight patients were included in the study with an overall complication rate of 2.8% over 5 years. No patients had postoperative bleeding or hematoma formation. One patient had a seroma, managed with ultrasound drainage. Complications requiring re-operation included rippling (3, 1.0%), pocket revision (2, 0.7%), capsule contracture (1, 0.3%) and rupture (1, 0.3%). This study highlights the safety and potential benefits of the use of topical TXA in breast augmentation, with low bleeding and capsular contracture rates.
Sections du résumé
BACKGROUND
BACKGROUND
Breast augmentation mammoplasty (BAM) remains to be the most popular cosmetic procedure done worldwide. Bleeding in this procedure increases the chance of capsular contracture. Tranexamic acid (TXA), an anti-fibrinolytic, has been widely used by other surgical specialties to reduce bleeding.
OBJECTIVES
OBJECTIVE
We aimed to evaluate the use of TXA in BAM surgery.
METHODS
METHODS
This is a single-surgeon case series of all patients who underwent primary BAM from March 2017 to March 2018 and received topical TXA spray to the implant pocket prior to implant insertion. Early postoperative complications and long-term outcomes, such as capsular contracture and revision surgery, were recorded and described.
RESULTS
RESULTS
Two hundred and eighty-eight patients were included in the study with an overall complication rate of 2.8% over 5 years. No patients had postoperative bleeding or hematoma formation. One patient had a seroma, managed with ultrasound drainage. Complications requiring re-operation included rippling (3, 1.0%), pocket revision (2, 0.7%), capsule contracture (1, 0.3%) and rupture (1, 0.3%).
CONCLUSIONS
CONCLUSIONS
This study highlights the safety and potential benefits of the use of topical TXA in breast augmentation, with low bleeding and capsular contracture rates.
Identifiants
pubmed: 37427875
pii: 7222144
doi: 10.1093/asj/sjad219
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of The Aesthetic Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.